Financial Position - As of December 31, 2023, the company had $11.9 million in money market investments, a decrease from $23.5 million at the end of 2022[527] - The company has not experienced any loss or write-down of money market investments for the years ended December 31, 2023, and 2022[527] - The investment policy prioritizes preservation of principal, liquidity, and return on investment, with minimal risk associated with fluctuating interest rates[528] Currency and Market Risks - The company is subject to foreign currency risks, holding approximately CAD$0.47 and €0.1 as of December 31, 2023[529] - Sales of PEDMARK® will depend on reimbursement by payers, which may be limited or unavailable in certain market segments[18] Product Development and Regulatory Approval - PEDMARK® has received marketing approval from the FDA and the European Commission, but further approvals from other foreign authorities are pending[15] - The company may require additional financing to obtain regulatory approval for and commercialize PEDMARK®, which could impact product development[13] Operational Challenges - The company has a history of significant losses and limited revenue generation from product sales since inception[13] - The ongoing COVID-19 pandemic may adversely affect the company's business and financial condition[13] - The company is highly dependent on a small number of key personnel and advisors, which poses a risk to its operations[18]

Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved PEDMARK Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and ...

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -600%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.07, delivering a surprise of 36.36%.Over the last four quarters, the company has surpassed ...

Fennec Pharmaceuticals Inc. (FENC) announced that it has entered into an exclusive licensing deal with Norgine, a European specialist pharmaceutical company, to develop and commercialize its only marketed product, Pedmark/Pedmarqsi (sodium thiosulfate injection), in EU, Australia and New Zealand.Fennec initially received FDA approval for Pedmark in 2022, granting marketing permission in the U.S. market as the first and only treatment to reduce the risk of ototoxicity (hearing loss) associated with cisplatin ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Inves ...

RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Time:L ...

RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Time ...

Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors Fennec will receive €40 million in upfront and up to €210 million in additional commercial and regulatory milestones, and tiered royalties up to the mid-twenties Enhances Norgine's commitment to bringing transformative therapies ...

Adherex Technologies Inc. (FENC) closed the last trading session at $9.72, gaining 3.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16 indicates a 64.6% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $0.71. While the lowest estimate of $15 indicates a 54.3% increase from the current price level, the most optimistic analy ...

FatCamera Fennec Pharmaceuticals – Revenue Guidance and EU Launch Fennec Pharmaceuticals (NASDAQ:FENC) (the Company), is a small cap, commercial-stage biotech company with a single drug, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate specifically developed for pediatric patients. PEDMARK is FDA-approved to reduce the risk of ototoxicity or hearing loss associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. The drug is used i ...